Trial Profile
Study of sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: highly effective amongst an OST cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Fibrosis; Hepatitis C
- Focus Therapeutic Use
- 17 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018